Skip to main content
Premium Trial:

Request an Annual Quote

Recent Payor Agreements Give Indi 200M-plus Covered Lives for Xpresys Lung Test

NEW YORK (GenomeWeb) – Integrated Diagnostics said today that recent payor decisions have given it more than 200 million covered lives for its Xpresys Lung cancer test.

The company has secured coverage agreements with UnitedHealthcare, MultiPlan, and preferred provider organizations FedMed, Fortified Provider Network, InterWest Health, Stratose, and Three Rivers Provider Network.

"These contracts demonstrate the game-changing clinical and economic value that Xpresys Lung offers," Indi CEO Albert Luderer said in a statement. "We are confident the cost savings associated with Xpresys Lung will assist with the efforts of providers and carriers to secure 'pay-for-performance' incentives under the Affordable Care Act."

Indi launched Xpresys Lung in October 2013 out of its CLIA lab. Intended to aid doctors in identifying lung nodules detected via CT scans as likely benign, Xpresys uses multiple-reaction monitoring mass spec to quantify the levels of 11 proteins in patient blood samples.

Beyond its potential clinical usefulness, the Xpresys test is also significant in that it is the first multiplexed proteomic test to go to market using MRM-MS on a triple quadrupole instrument.